NXL
HEALTHCARENexalin Technology Inc
Live · NASDAQ · May 9, Close
What's Moving NXL Today?
No stock-specific AI insight has been generated for NXL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.35
Fundamentals
Trading
NXL News
20 articles- Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic InsomniaYahoo Finance·Apr 28, 2026
- Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 EnrollmentYahoo Finance·Apr 22, 2026
- RedChip's Biotech Investor Conference Replays Now AvailableYahoo Finance·Apr 20, 2026
- April 2026 Global's Top Undervalued Small Caps With Insider ActionYahoo Finance·Apr 17, 2026
- ASX Stocks That May Be Trading Below Their Estimated ValueYahoo Finance·Apr 16, 2026
- Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and ChinaYahoo Finance·Apr 15, 2026
- Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21Yahoo Finance·Apr 14, 2026
- Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsGlobeNewswire Inc.·Apr 9, 2026
- RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceYahoo Finance·Apr 2, 2026
- Three High Growth Tech Stocks in AustraliaYahoo Finance·Mar 29, 2026
- Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia MarketYahoo Finance·Feb 24, 2026
- Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological DisordersYahoo Finance·Feb 23, 2026
- Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Feb 13, 2026
- Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD CareYahoo Finance·Feb 5, 2026
- Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain StimulationYahoo Finance·Feb 2, 2026
- Nexalin Technology Receives Nasdaq Listing Status NotificationYahoo Finance·Jan 23, 2026
- Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHDYahoo Finance·Jan 14, 2026
- Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease ProgramYahoo Finance·Dec 3, 2025
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4Yahoo Finance·Dec 2, 2025
- Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use ComorbidityYahoo Finance·Nov 18, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.35
Fundamentals
Trading
About Nexalin Technology Inc
Nexalin Technology Inc. is an innovative leader in the medical technology industry, dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. These non-invasive therapies target conditions such as anxiety, depression, and substance addiction, reflecting the company's commitment to advancing mental health solutions. With a robust foundation in research and a clear strategic focus on improving patient outcomes, Nexalin is well-positioned to leverage the increasing demand for cutting-edge healthcare innovations, indicating significant growth potential in the dynamic digital health marketplace.